Gabelli Funds LLC Has $8.24 Million Position in ICU Medical, Inc. $ICUI

Gabelli Funds LLC lessened its position in ICU Medical, Inc. (NASDAQ:ICUI) by 7.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,792 shares of the medical instruments supplier’s stock after selling 4,808 shares during the period. Gabelli Funds LLC owned about 0.26% of ICU Medical worth $8,239,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Hilton Head Capital Partners LLC acquired a new stake in ICU Medical in the 4th quarter valued at about $32,000. Covestor Ltd raised its stake in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 126 shares during the period. Strs Ohio raised its stake in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after buying an additional 300 shares during the period. Rockefeller Capital Management L.P. lifted its position in shares of ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of ICU Medical in the fourth quarter valued at approximately $120,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Price Performance

ICU Medical stock opened at $161.46 on Tuesday. The company has a market capitalization of $4.03 billion, a price-to-earnings ratio of 87.28, a PEG ratio of 2.20 and a beta of 0.76. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $162.85. The stock’s 50 day moving average is $144.98 and its 200-day moving average is $139.78.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, topping the consensus estimate of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm’s revenue for the quarter was down 12.3% compared to the same quarter last year. During the same period last year, the firm posted $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities research analysts expect that ICU Medical, Inc. will post 6.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ICUI. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 27th. KeyCorp raised their price target on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Piper Sandler dropped their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $172.00.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.